CAR-T Cell Therapy for Pediatric Oncology: The Peril and the Promise
March 5, 2018 | 12:00 PM | Li Ka Shing Center 102

WITH OPENING BY
MARY LEONARD, MD, MSCE
Dr. Mary Leonard is the Arline and Pete Harman Professor and Chair in the Department of Pediatrics at the Stanford School of Medicine. She is Physician-in-Chief at the Lucile Packard Children's Hospital and the executive director of the Stanford Child Health Research Institute.

SPEAKER
CRYSTAL MACKALL, MD
Endowed Professor of Pediatrics and Medicine, Stanford University
Dr. Crystal Mackall serves as Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program at Stanford and Director of the Parker Institute for Cancer Immunotherapy at Stanford. During her tenure as Head of the Immunology Section and Chief of the Pediatric Oncology Branch, NCI, she built an internationally recognized translational research program spanning basic studies of T cell homeostasis and tumor immunology, and clinical trials of immune based therapies for cancer. Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. She is currently a mentor to a CHRI-funded clinical trainee.

SPEAKER
CHRISTOPHER MOUNT
Graduate Student, Neuroscience Program, Stanford University
Chris graduated from the University of Washington in 2011 with a B.S. in Bioengineering. He is currently a Stanford MD/PhD student and a member of the Neuroscience graduate program in Dr. Michelle Monje’s laboratory. In the Monje lab, his work is focused on the intersection between neural development and neuro-oncology. Recently, he has worked with the SPARK program to bring engineered T cell therapies to bear against preclinical models of pediatric brain tumors.

LUNCH PROVIDED! LIMITED SEATING.
REGISTER: https://chri-seminars-mar5.eventbrite.com